Answers are grounded in this paper and cite their sources.
In patients with transthyretin amyloid cardiomyopathy, tafamidis was associated with reductions in all-cause mortality and cardiovascular-related hospitalizations and reduced the decline in functional capacity and quality of life as compared with placebo. (Funded by Pfizer; ATTR-ACT ClinicalTrials.gov number, NCT01994889 .).
No takes yet. Share an insight, caveat, or question.
Maurer et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: